Chronic Periodontitis Clinical Trial
Official title:
Evaluation of the Efficacy of a Novel Synthetic Bone Regeneration Material (Sil-Oss®) In the Treatment of Periodontal Intrabony Osseous Defects
Siloss® (Azurebio, Madrid, Spain) is a synthetic and inorganic bone graft material and is
composed of a dicalcium phosphate anhydrous (monetite), hydroxyapatite (HA), and amorphous
silica and trace amounts of zinc. It is manufactured by a proprietary process avoiding high
temperatures. This results in a non-sintered material with a high specific surface area (65
m2/g) and high interconnected porosity (60%) that favour a high degree of interaction with
its biological surrounding. It is fully resorbable, being replaced by natural bone, thereby
avoiding the disadvantages of nonresorbable materials that interfere with normal processes
of bone remodelling. Siloss® is resorbed both by a dual process of slow dissolution of its
components and by active cellular remodelling. Controlled dissolution of Siloss® releases
Ca, P, Si and Zn that stimulate regeneration processes while larger pores are formed
allowing colonization of osteoclasts and osteoblasts involved in bone remodelling. It
functions as a bioactive temporary scaffold maintaining the desired volume while it promotes
bone regeneration and is being replaced by new vascularized bone. The alloplastic property
of the graft material avoids the risk of infection and adverse inflammatory reactions. Also,
resorption of Siloss® prevents possible adverse effects associated with long permanence of
low resorbable materials.
The aim of the present study is to clinically and radiographically evaluate the efficacy of
bone graft material (Siloss ®) in the treatment of intrabony defects.
Study design The study was designed as a split-mouth, double-blind, randomized controlled
clinical trial. The purpose of this study is to evaluate the efficacy of a novel synthetic
bone regeneration material (Siloss®) in the treatment of periodontal intrabony osseous
defects. Ethical clearance has been obtained from the institutional ethical committee with
participants signing an informed consent prior to the commencement of the study.
Sample Size calculation Sample size was calculated by considering this trial as a
non-inferiority trial. A minimum sample size of 27 will be required when the minimum
difference of mean bone fill levels before and after treatment is to be at least 1mm2 at
p=0.05 with expected variance of 0.8 for having ß=0.1.
Source of data A total of 30 subjects were selected from the outpatient section of the
Department of Periodontics. Systemically healthy chronic periodontitis subjects within the
age group of 30-55 years having at least 2 periodontal pockets ≥5 mm with at least 1 pocket
in each quadrant showing ra¬diographic evidence of vertical bone loss were included in the
study. Patients who underwent periodontal therapy in the past 6 months and/or have used
antibiotic drugs, antioxidants, and antibacterial mouthwash or medicated toothpastes within
6 months of baseline and smokers were excluded from the study. Assessment of suitability for
bone graft was confirmed by transgingival probing to verify the presence of well-contained
interdental bone defects in as many quadrants.
Randomization and Blinding Randomization and blinding included computerized generation of
the allocation sequence in random permuted blocks (block randomization) and blinded
disbursement of medication. Allocation was performed by assigning the block of sites to
study groups according to the specified sequence. Based on the sequence, the first operator
selected two sites for each of the following experimental sites; the test site, in which
graft (Siloss®) was placed and the control site which was treated by Hydroxyapatite graft
only. All the surgeries were performed by a designated operator for the sake of uniformity
whereas the relevant readings were recorded by the first operator who was blinded to the
nature of the site. The blind was not broken until this clinical trial was completely
finished.
Standardization of PPD and CAL PPD and CAL were recorded at the baseline and at the end of
3, 6 and 9 months using a UNC-15 color-coded periodontal probe. An alginate impression was
taken and custom acrylic stent limited to the occlusal 2/3rds of the clinical crown were
used as fixed reference position (i.e. junction of vertical groove and lower border of the
stent). A groove was prepared in the stent to standardize the probing angulation throughout
the study period.
Standardization of radiographs Standard digital IOPA radiographs were taken at baseline, 3
and 6 months by the paralleling/long-cone technique at preset parameters using a
commercially available RVG (Radiovisiography) system (Kodak RVG 5100® Digital Radiography
System, Carestream Health, Rochester, USA). After the imaging plate was placed in the film
holder for paralleling technique (XCP Kits for Digital Sensors®, BlueDent, Chennai, India),
addition silicon impression material (Elite HD+ Regular Body Normal Set®, Zhermack, Badia
Polesine, Italy) was added around the biting surface and allowed to set. This arrangement
ensured standardized alignment of the aiming device and the holder ensuring correct
positioning of the collimator in subsequent radiographs.
Presurgical protocol Each patient was prepared for surgery with oral hygiene instructions,
scaling and root planing at least three months prior to surgery, adjunctive chemical plaque
control, and occlusal adjustment was performed, whenever necessary. Patients were
re-evaluated to assess clinical parameters and plaque control four weeks after initial
therapy.
Study protocol After the interdental areas were probed buccally and lingually/ palatally,
the site was considered for study if the average probing pocket depth (PPD) was ≥5 mm. All
baseline (on the day of surgery) parameters were recorded before the surgical procedure. The
PPD, CAL and site specific plaque scores were recorded at the baseline and at the end of 3,
6 and 9 months. Clinical parameters were recorded using a University of North Carolina no.15
(UNC-15) color-coded Surgical procedure At the start of the surgical procedure, the patients
were asked to rinse with 0.2 % chlorhexidine for 1 min. Area subjected to surgery was
anesthetized by nerve block/infiltration depending on the surgical site using local
anaesthesia. Crevicular incisions were made and the flaps were elevated by means of blunt
dissection with the help of a periosteal elevator. The osseous defect was debrided of
granulation tissue and the root surface was planed to remove plaque and calculus, until a
smooth hard consistency was found. The defect's architecture was confirmed by direct
observation and classified based on number of bony walls present. In patients selected for
test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was
utilized to fill the defects to the most coronal level of the osseous walls. The required
amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed
with patients own blood and carried to the defect site with an amalgam carrier. The
mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The
surgical procedure in control site included open flap debridement followed by placement of
hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and
covered using a periodontal dressing.
Follow-up and postsurgical care Routine postoperative instructions, oral antimicrobials
(amoxicillin 500 mg, TID), and analgesics (Diclofenac sodium 50 mg + Paracetamol 325 mg BID)
were prescribed for 5 days post operatively and routine post-surgical instructions were
explained. Patients were instructed to rinse with 10 ml of 0.2 % chlorhexidine mouthwash
twice daily for a week. They were advised to avoid chewing on the surgical site and told not
to brush at the site or manipulate it for 10 days one week after the surgery, the dressing
and the sutures were removed. Oral hygiene instructions were reinforced. Patients were then
monitored at 3, 6, and 9 months. At each of the recall visits, reinforcement of oral hygiene
measures, and supragingival scaling if required were performed. At 6 months, all soft tissue
measurements were repeated.
Radiographic assessment A single operator evaluated the bone fill by using digital
subtraction technique and morphometric area analysis by using specific tools in two image
processing software according to a previously described method.
Digital subtraction technique and Morphometric Analysis The radiographs obtained at 3 and 6
months were subtracted from the radiograph taken at the baseline by using commercially
available image processing software (Adobe Photoshop® 6.0, Adobe Systems, San Jose, USA). To
reduce brightness and contrast variations, both images were adjusted based on the levels and
curves in the software. Before digital subtraction, both radiographs were moved in
appropriate directions as needed, to reduce geometric distortion. These images were then
superimposed and subtracted by selecting the image > calculation> exclusion > new channel
tools. The excluded interdental layer was outlined by using the polygonal lasso tool and the
layer was copied and saved as a separate joint photographic expert group document at low
compression. Morphometric area analysis. After digital subtraction, the digitized and
excluded interdental layer was transferred to open source software for area calculation
(ImageJ®, Research Services Branch, NIH, Bethesda, Maryland, USA) for area calculation. The
layer was converted into a grayscale image, and the measurement scale was set to account for
any magnification/reduction of the radiograph because of RVG. The area of the layer was
calculated (in mm2) by initially enclosing the entire area with the rectangular selection
tool and then by using Analyze > Analyze Particles tool.
Histomorphometric analysis From 3 subjects each from both the groups, bone biopsy specimens
were obtained during crown lengthening procedures between 71/2 to 9 months. Briefly, the
specimens were immersed in 4% buffered formalin and were subsequently dehydrated in an
ascending series of ethyl alcohols. The specimens were then stained using haematoxylin-eosin
for light microscopy analysis. 11 and 12 slides were prepared from SILOSS® and HA groups
respectively. 10 regions of interest (ROIs) per slide were visualized for mineralized tissue
volume by using an Olympus BX 53 microscope at 40X magnification. Before evaluation of bone
sections in ImageJ, black and white image masks were created using Adobe Photoshop®
according to a technique described by Egan et al.
Calibrating ImageJ To calibrate Image J, a scale bar was placed on one image for each
magnification. The file was opened with an image containing a scale bar inserted by the
microscope or camera software that acquired the image. The length measured for the scale bar
was entered as distance in pixels. The length of the scale bar as labelled by the microscope
is entered as known distance and subsequent analysis was measured on this scale.
Quantifying the Mineralized Tissue Volume in ImageJ The bone volume mask file was opened and
the total area was selected by Edit> Selection>Select All and Click Analyze>Measure. The
"wand tool" and shift key were used to select the black areas. Selecting Analyze>Measure
will quantify the mineralized tissue. The Mineralized Tissue Volume was expressed as
(mineralized tissue/total area)*100.
Statistical Analysis Site-specific intragroup comparison between various groups was
performed using ANOVA followed by multiple comparisons using Bonferroni correction. One-way
ANOVA followed by the post hoc test was used for intragroup and intergroup comparison. A
p-value of <0.05 was considered statistically significant and p-value of <0.001 was
considered as highly significant
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06400069 -
Role of NLRP6 in Chronic Periodontitis
|
||
Completed |
NCT05231096 -
Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis
|
N/A | |
Completed |
NCT03203746 -
Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Completed |
NCT02516111 -
Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment
|
Phase 2/Phase 3 | |
Terminated |
NCT02568163 -
Influence of Stress on Non Surgical Periodontal Treatment
|
N/A | |
Completed |
NCT02174146 -
Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy
|
N/A | |
Completed |
NCT02430519 -
Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects
|
N/A | |
Completed |
NCT01233765 -
Analysis of Neutrophil Response in Chronic Periodontitis
|
N/A | |
Completed |
NCT01438333 -
Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection
|
N/A | |
Completed |
NCT02218515 -
Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft
|
Phase 4 | |
Completed |
NCT02197260 -
Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing
|
Phase 4 | |
Not yet recruiting |
NCT03270280 -
Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis
|
Phase 2 | |
Not yet recruiting |
NCT04026828 -
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
|
||
Completed |
NCT04643288 -
Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects
|
N/A | |
Completed |
NCT04697199 -
The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis
|
Phase 1 | |
Completed |
NCT03039244 -
Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers
|
N/A | |
Completed |
NCT02898675 -
Advantages of Autologous Platelet-Rich Fibrin Membrane on Growth Factor Levels and Periodontal Healing
|
N/A | |
Completed |
NCT02851823 -
Combined Use of Er:YAG and Nd:YAG Laser
|
N/A | |
Completed |
NCT02518152 -
Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis
|
Phase 2/Phase 3 |